Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$4.6M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$233M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Kumar Neil | Nov 19, 2024 | Sell | 25,514 | $22.3856 | $570,000 |
| Kumar Neil | Nov 19, 2024 | Sell | 1,875 | $22.7625 | $43,000 |
| STEPHENSON BRIAN C | Nov 19, 2024 | Sell | 4,156 | $22.4102 | $93,000 |
| KRAVIS HENRY R | Sep 13, 2024 | Sell | 5,800,000 | $25.75 | $149M |
| Kumar Neil | Aug 19, 2024 | Sell | 16,192 | $24.3879 | $390,000 |
| Kumar Neil | Aug 19, 2024 | Sell | 11,197 | $25.1288 | $280,000 |
| STEPHENSON BRIAN C | Aug 19, 2024 | Sell | 2,457 | $24.3878 | $60,000 |
| STEPHENSON BRIAN C | Aug 19, 2024 | Sell | 1,698 | $25.1288 | $43,000 |
| Scott Randal W. | Jun 4, 2024 | Sell | 1,500 | $31.3 | $47,000 |
| Scott Randal W. | Jun 3, 2024 | Sell | 800 | $28.6844 | $23,000 |
| Scott Randal W. | Jun 3, 2024 | Sell | 200 | $29.475 | $5,900 |
| Scott Randal W. | Mar 1, 2024 | Sell | 2,500 | $34 | $85,000 |
| Valantine Hannah | Feb 15, 2024 | Sell | 2,915 | $37.75 | $110,000 |
| Valantine Hannah | Jan 16, 2024 | Sell | 2,915 | $37.97 | $110,000 |
| MCCORMICK FRANK | Dec 26, 2023 | Sell | 100,000 | $42.06 | $4.2M |
| Scott Randal W. | Dec 18, 2023 | Sell | 2,000 | $40 | $80,000 |
| Valantine Hannah | Dec 15, 2023 | Sell | 2,915 | $36.12 | $110,000 |
| Scott Randal W. | Dec 1, 2023 | Sell | 1,500 | $30 | $45,000 |
| Scott Randal W. | Dec 1, 2023 | Sell | 1,000 | $28.5 | $29,000 |
| STEPHENSON BRIAN C | Nov 17, 2023 | Sell | 22,685 | $29.0967 | $660,000 |
| Kumar Neil | Nov 17, 2023 | Sell | 51,352 | $29.0958 | $1.5M |
| Kumar Neil | Nov 17, 2023 | Sell | 200 | $29.55 | $5,900 |
| Valantine Hannah | Nov 15, 2023 | Sell | 2,915 | $30 | $87,000 |
| Scott Randal W. | Sep 5, 2023 | Sell | 2,500 | $30 | $75,000 |
| STEPHENSON BRIAN C | Aug 17, 2023 | Sell | 22,683 | $28.5877 | $650,000 |
| Kumar Neil | Aug 17, 2023 | Sell | 51,552 | $28.5883 | $1.5M |
| VIKING GLOBAL INVESTORS LP | Jul 18, 2023 | Sell | 1,500,000 | $35 | $53M |
| Kumar Neil | May 17, 2023 | Sell | 51,552 | $14.0095 | $720,000 |
| STEPHENSON BRIAN C | May 17, 2023 | Sell | 24,424 | $14.0095 | $340,000 |
| Kumar Neil | May 3, 2023 | Sell | 120,000 | $14.1812 | $1.7M |
| STEPHENSON BRIAN C | May 3, 2023 | Sell | 64,929 | $14.18 | $920,000 |
| Kumar Neil | Apr 5, 2023 | Sell | 120,000 | $15.4638 | $1.9M |
| STEPHENSON BRIAN C | Apr 5, 2023 | Sell | 55,500 | $15.454 | $860,000 |
| Kumar Neil | Mar 3, 2023 | Sell | 120,000 | $10.9602 | $1.3M |
| STEPHENSON BRIAN C | Mar 3, 2023 | Sell | 62,692 | $10.9607 | $690,000 |
| STEPHENSON BRIAN C | Feb 17, 2023 | Sell | 15,567 | $12.6535 | $200,000 |
| Kumar Neil | Feb 17, 2023 | Sell | 44,798 | $12.7031 | $570,000 |
| STEPHENSON BRIAN C | Feb 17, 2023 | Sell | 2,150 | $13.0646 | $28,000 |
| Kumar Neil | Feb 3, 2023 | Sell | 120,000 | $11.0058 | $1.3M |
| STEPHENSON BRIAN C | Feb 3, 2023 | Sell | 61,040 | $11.0079 | $670,000 |
| Kumar Neil | Jan 5, 2023 | Sell | 120,000 | $7.6738 | $920,000 |
| STEPHENSON BRIAN C | Jan 5, 2023 | Sell | 61,040 | $7.6748 | $470,000 |
What's the latest insider transaction for BridgeBio Pharma?
The most recent insider transaction for BridgeBio Pharma was conducted by Kumar Neil, who sold 25,514 shares on November 19, 2024 at a price of $22.39 per share.
Which insider has sold the most BBIO stock over the last two years?
KRAVIS HENRY R has sold the most BBIO stock in the last 2 years, with a total value of $149M.
What is the total value of insider transactions for BridgeBio Pharma (BBIO) in the last 2 years?
The total value of insider transactions for BridgeBio Pharma in the last 2 years is negative, amounting to -$225M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on BridgeBio Pharma's market confidence?
Over the last 2 years, insider transactions for BridgeBio Pharma have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
